JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS Vol. 33, no. 4, 1019-1022 (2019)
Mesenchymal stem cells and IL-37: a powerful combination.
- 1 IRCCS Centro Neurolesi “Bonino Pulejo”, Messina, Italy.
- 2 School of Pharmacy, University of Camerino, Camerino, Italy.
- 3 Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Ferrara, Italy.
- 4 Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle University of Thessaloniki, Macedonia, Greece.
- 5 Clinica dei Pazienti del Territorio, Fondazione Policlinico Gemelli, Rome, Italy.
- 6 Department of Oral and Biotechnology Medical Science, University of Chieti-Pescara, Chieti, Italy.
- 7 Postgraduate Medical School, University of Chieti, Chieti, Italy.
- 8 Maxillofacial Surgery “G. Mazzini” Hospital, Teramo, Italy.
Mesenchymal stem cells (MSCs) are able to exert immunomodulatory and anti-inflammatory actions. Thanks to these properties, MSCs may be a promising alternative approach for the treatment of inflammatory disease. Important cytokines involved in inflammation are those included in the IL-1 family. Interleukin-37 (IL-37) is one of the member able to suppress both innate and adaptive immunity. Recently, it was found that MSCs and their derivatives can modulate IL-37, and MSCs expressing IL-37 seem to have an enhanced therapeutic efficacy.
Copyright 2019 Biolife Sas. www.biolifesas.org.
IL-37, inflammation, mesenchymal stem cells